On this episode of Stock Movers:

- Oracle (ORCL) fell after giving its long-range financial outlook, suggesting investors anticipated a bigger boost from its investment in AI infrastructure. The company said overall annual revenue would total $225 billion by fiscal 2030, and the cloud infrastructure business would produce $144 billion in sales by then. Investors have expressed concern about the profitability of Oracle's AI effort, but the company said an infrastructure project for AI would have a gross margin of 35%.

- American Express (AXP) reported earnings that beat expectations after unveiling the long-anticipated Platinum credit card refresh last month. Initial demand for the revamped Platinum card exceeded the firm’s predictions, with US Platinum account acquisitions doubling from pre-refresh levels. The firm raised the lower end of its full-year guidance, with revenue now expected to grow 9% to 10% and earnings likely to total $15.20 to $15.50 a share.

- Eli Lilly (LLY) and Novo Nordisk shares fell after President Donald Trump said the price of the diabetes drug Ozempic could come down to just $150 a month. Trump told reporters that the cost of the drug will soon be “much lower” than the current US list price of roughly $1,000 for a month’s supply. The potential price cut could lead to a big hit for Novo and Lilly, which dominate a market expected to top $95 billion by 2030

On this episode of Stock Movers: - Oracle (ORCL) fell after giving its long-range financial outlook, suggesting investors anticipated a bigger boost from its investment in AI infrastructure. The company said overall annual revenue would total $225 billion by fiscal 2030, and the cloud infrastructure business would produce $144 billion in sales by then. Investors have expressed concern about the profitability of Oracle's AI effort, but the company said an infrastructure project for AI would have a gross margin of 35%. - American Express (AXP) reported earnings that beat expectations after unveiling the long-anticipated Platinum credit card refresh last month. Initial demand for the revamped Platinum card exceeded the firm&rsquo;s predictions, with US Platinum account acquisitions doubling from pre-refresh levels. The firm raised the lower end of its full-year guidance, with revenue now expected to grow 9% to 10% and earnings likely to total $15.20 to $15.50 a share. - Eli Lilly (LLY) and Novo Nordisk shares fell after President Donald Trump said the price of the diabetes drug Ozempic could come down to just $150 a month. Trump told reporters that the cost of the drug will soon be &ldquo;much lower&rdquo; than the current US list price of roughly $1,000 for a month&rsquo;s supply. The potential price cut could lead to a big hit for Novo and Lilly, which dominate a market expected to top $95 billion by 2030

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Oracle Falls, American Express Surges, Eli Lilly Falls on 'Cheap Weight Loss Dugs'

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/e3815081-c138-4b30-9704-b379013dc899/transcript

Advertisement